Clinical effect of calcium carbonate D3 combined with recombinant human growth hormone on idiopathic short-stature children
Objective:To analyze the clinical effect of calcium carbonate D3 combined with recombinant human growth hormone in children with idiopathic short stature.Method:From January 2023 to January 2024,66 children with idiopathic short stature in our hospital were randomly divided into the observation group and the control group(n=33).The control group was treated with subcutaneous injection of recombinant human growth hormone 0.1 IU·kg-1,and the observation group was treated with calcium carbonate D3 orally at 14 mg·kg-1.After continuous treatment for 1 year,height was measured,bone age maturity was evaluated by X-ray examination,and growth factor level was detected by enzyme-linked immunosorbent assay.Results:After treatment,the height,growth rate,and height standard deviation of the observation group were better than those of the control group(P<0.05).The bone age index and bone age difference in the observation group were better than those in the control group(P<0.05).The level of growth factors in the observation group was higher than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion:Calcium carbonate D3 combined with recombinant human growth hormone can effectively improve the calcium level,bone maturity,and growth factor levels in children with idiopathic short stature,promoting growth and development.
Idiopathic short statureCalcium carbonate D3Recombinant human growth hormoneTreatment effect
万方数据
维普
